Biotech startups – are you looking to raise private financing, or seeking regional or global licensing deals?
This virtual Lunch & Learn is for anyone who is seeking to raise a private financing round, or seeking a regional or global licensing deal for a preclinical-stage program, clinical-stage program, or technology.
Licensing is one of the most common collaborations in the life-science industry and licensing cash flows are also a significant source of non-dilutive financing. However, how to effectively license-in/out an asset can be one of the obstacles, as these require connections and experiences. In this presentation, Gemseki will share the know-how of licensing and its Drug Candidate Marketplace with the audience.
About the Speaker:
Sanjeev Balhara is a Vice President for Business Development of Gemseki.
From 2008 to 2018, Sanjeev worked as Chief Investment Officer and VP Corporate Development at Ignyta, an oncology company (NASDAQ: RXDX), and as Vice President at Third Security, a life sciences venture capital firm with assets of $2B AUM. He participated in search and evaluation of licensing, merger and acquisition opportunities in biotech and pharma. Some of the BD activities that Sanjeev participated in include the sale of Clinical Data to Forest for $1.2B, sale of genomic tests business to Transgenomics for $15 million, acquisition of pipeline drugs from Teva for $15M stock, acquisition of a pipeline drug from Eli Lilly for $2M cash and $12M stock, and $100M+ in follow-on investments in Intrexon, Clinical Data and Halozyme.
He has a Bachelor in Electrical Engineering degree from the Indian Institute of Technology, Varanasi, India and an MBA from the Wharton School, University of Pennsylvania.
Thank you to our sponsor, Gemseki.
Founded in 2017, Gemseki is a Tokyo-based company with multinational members worldwide specializing in business development and licensing for the bio-industry. Recently, we successfully facilitated an international industry-academia collaboration between Harvard and Kyowa Kirin. With more than 300 assets listed, Gemseki’s ‘Drug Candidate Marketplace’ serves as a digital platform to connect the licensing partners to accelerate drug developments and the platform is widely used by visitors from 100+ countries.